|
|
 Previous Article | Table of Contents | Next Article 
Basic fibroblast growth factor expression in human bone marrow and
peripheral blood cells
G Brunner, H Nguyen, J Gabrilove, DB Rifkin and EL Wilson
Department of Cell Biology, New York University Medical Center, NY 10016.
We have shown previously that basic fibroblast growth factor (bFGF) is a
mitogen for human bone marrow (BM) stromal cells and that bFGF stimulates
myelopoiesis in primary BM cultures. In this article, we demonstrate the
presence of bFGF in two cell lineages in human BM and peripheral blood as
well as the deposition of bFGF into the extracellular matrix of BM stromal
cell cultures. In immunofluorescence experiments on BM and peripheral blood
smears, megakaryocytes and platelets stained strongly for bFGF, whereas
weaker staining was observed in immature and mature cells of the
granulocyte series. The presence of bFGF in platelets was confirmed by
enzyme-linked immunosorbent assay as well as by immunoprecipitation
followed by immunoblotting. bFGF was synthesized by BM stromal cell
cultures and was found either cell associated or localized in the nucleus
and the nucleoli, and its location was dependent on the fixation procedure
used. Addition of exogenous bFGF to stromal cells showed the presence of
extracellular binding molecules for this cytokine. bFGF could be released
from these sites by soluble heparin or phosphatidylinositol- specific
phospholipase C. This study supports the role of bFGF as a stromal cell
mitogen and stimulator of myelopoiesis. The data indicate that the stromal
cells produce bFGF and that their extracellular matrix can serve as a
reservoir for this growth factor. In addition, the results suggest a
possible involvement of bFGF in platelet function as well as in
megakaryocytopoiesis.
Volume 81,
Issue 3,
pp. 631-638,
02/01/1993
Copyright © 1993 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
D. M. Ranly, C. H. Lohmann, D. Andreacchio, B. D. Boyan, and Z. Schwartz
Platelet-Rich Plasma Inhibits Demineralized Bone Matrix-Induced Bone Formation in Nude Mice
J. Bone Joint Surg. Am.,
January 1, 2007;
89(1):
139 - 147.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Podar and K. C. Anderson
The pathophysiologic role of VEGF in hematologic malignancies: therapeutic implications
Blood,
February 15, 2005;
105(4):
1383 - 1395.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Brill, H. Elinav, and D. Varon
Differential role of platelet granular mediators in angiogenesis
Cardiovasc Res,
August 1, 2004;
63(2):
226 - 235.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Korah, M. Boots, and R. Wieder
Integrin {alpha}5{beta}1 Promotes Survival of Growth-Arrested Breast Cancer Cells: An in Vitro Paradigm for Breast Cancer Dormancy in Bone Marrow
Cancer Res.,
July 1, 2004;
64(13):
4514 - 4522.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Chen, Z. G. Zhang, Y. Li, L. Wang, Y. X. Xu, S. C. Gautam, M. Lu, Z. Zhu, and M. Chopp
Intravenous Administration of Human Bone Marrow Stromal Cells Induces Angiogenesis in the Ischemic Boundary Zone After Stroke in Rats
Circ. Res.,
April 4, 2003;
92(6):
692 - 699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Ruotsalainen, H. Joensuu, K. Mattson, and P. Salven
High Pretreatment Serum Concentration of Basic Fibroblast Growth Factor Is a Predictor of Poor Prognosis in Small Cell Lung Cancer
Cancer Epidemiol. Biomarkers Prev.,
November 1, 2002;
11(11):
1492 - 1495.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. S. Go, A. L. Horstman, K. Neben, and H. Goldschmidt
Correspondence re: K. Neben et al., High Plasma Basic Fibroblast Growth Factor Concentration Is Associated with Response to Thalidomide in Progressive Multiple Myeloma. Clin. Cancer Res., 7: 2675-2681, 2001.
Clin. Cancer Res.,
August 1, 2002;
8(8):
2750 - 2751.
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. T.-P. Poon, S.-T. Fan, and J. Wong
Clinical Implications of Circulating Angiogenic Factors in Cancer Patients
J. Clin. Oncol.,
February 15, 2001;
19(4):
1207 - 1225.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, A. Orpana, L. Teerenhovi, and H. Joensuu
Simultaneous elevation in the serum concentrations of the angiogenic growth factors VEGF and bFGF is an independent predictor of poor prognosis in non-Hodgkin lymphoma: a single-institution study of 200 patients
Blood,
December 1, 2000;
96(12):
3712 - 3718.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Sungaran, O. T. Chisholm, B. Markovic, L. M. Khachigian, Y. Tanaka, and B. H. Chong
The role of platelet alpha -granular proteins in the regulation of thrombopoietin messenger RNA expression in human bone marrow stromal cells
Blood,
May 15, 2000;
95(10):
3094 - 3101.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Browder, J. Folkman, and S. Pirie-Shepherd
The Hemostatic System as a Regulator of Angiogenesis
J. Biol. Chem.,
January 21, 2000;
275(3):
1521 - 1524.
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Salven, L. Teerenhovi, and H. Joensuu
A High Pretreatment Serum Basic Fibroblast Growth Factor Concentration Is an Independent Predictor of Poor Prognosis in Non-Hodgkin's Lymphoma
Blood,
November 15, 1999;
94(10):
3334 - 3339.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bikfalvi, S. Klein, G. Pintucci, and D. B. Rifkin
Biological Roles of Fibroblast Growth Factor-2
Endocr. Rev.,
February 1, 1997;
18(1):
26 - 45.
[Abstract]
[Full Text]
|
|
|
|
|
